Akouos Overview

  • Founded
  • 2016

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 97

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $449M

Akouos General Information

Description

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders, thereby enabling its clients to be provided with advancing precision genetic therapies with the potential to restore, improve and preserve hearing.

Contact Information

Website
www.akouos.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Eli Lilly
Primary Office
  • 645 Summer Street
  • Suite 200
  • Boston, MA 02210
  • United States
+1 (857) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akouos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-Dec-2022 $449M 00000 00000 Completed Generating Revenue
6. IPO 26-Jun-2020 00000 00000 00000 Completed Generating Revenue
5. Early Stage VC (Series B) 03-Mar-2020 00000 00000 00000 Completed Startup
4. Early Stage VC (Series A) 07-Aug-2018 0000 000.00 0000 Completed Startup
3. Seed Round 13-Nov-2017 00.000 00.000 000.00 Completed Startup
2. Accelerator/Incubator 05-Oct-2017 Completed Startup
1. Accelerator/Incubator 13-Oct-2016 Completed Startup
To view Akouos’s complete valuation and funding history, request access »

Akouos Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed I 2,058,855 $0.000100 $0.02 $0.24 $0.24 1x $0.24 0.41%
Seed 25,622,520 $0.000100 $0.02 $0.28 $0.28 1x $0.28 5.06%
To view Akouos’s complete cap table history, request access »

Akouos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearin
Drug Discovery
Boston, MA
97 As of 2023
00000
0000 0000-00-00
000000&0 00000

000000

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000 000000000
Boston, MA
00 As of 0000
00000
0000 0000-00-00
000000&0 00000

000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akouos Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Decibel Therapeutics Formerly VC-backed Boston, MA 00 00000 000000&0 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Stevenage, United Kingdom 00 000.00 000000 - 000 000.00
000000000 00000000 Formerly VC-backed Lexington, MA 00 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
You’re viewing 5 of 14 competitors. Get the full list »

Akouos Patents

  • 71

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 13

    Pending

  • 000

    Expiring in next 12 mo

Akouos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021412962-A1 Compositions and methods for treating clrn1-associated hearing loss and/or vision loss Pending 29-Dec-2020 000000000
CA-3203373-A1 Compositions and methods for treating clrn1-associated hearing loss and/or vision loss Pending 29-Dec-2020 000000000
AU-2021391433-A1 Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms Pending 01-Dec-2020 000000000
CA-3197936-A1 Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms Pending 01-Dec-2020 000000000
US-20230295287-A1 Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms Pending 01-Dec-2020 C07K16/22
To view Akouos’s complete patent history, request access »

Akouos Executive Team (17)

Name Title Board Seat Contact Info
Jennifer Wellman Chief Operating Officer
Karoline Shair Chief Legal Officer & Corporate Secretary
Aaron Tward Chief Scientific Officer
Gregory Robinson Ph.D Chief Scientific Officer
Luk Vandenberghe Ph.D Co-Founder & Member of Scientific Advisory Board
You’re viewing 5 of 17 executive team members. Get the full list »

Akouos Board Members (7)

Name Representing Role Since
Edward Mathers New Enterprise Associates Board Member 000 0000
Kush Parmar Ph.D 5AM Ventures Board Member 000 0000
Vicki Sato Ph.D Self Board Member 000 0000
You’re viewing 3 of 7 board members. Get the full list »

Akouos Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akouos Former Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Citadel Enterprise Americas Hedge Fund Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Cowen Healthcare Investments Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial